GlobalData analysed the number of clinical trials examining cystic fibrosis with start dates...
EUSA Pharma wins FDA approval for trial of siltuximab to treat ARDS
EUSA Pharma has secured approval from the US Food & Drug Administration (FDA) for a Phase III clinical trial protocol of intravenous siltuximab plus standard of care in hospitalised patients with Covid-19 associated Acute Respiratory Distress Syndrome (ARDS).
AstraZeneca’s Breztri Aerosphere reduces COPD exacerbations
AstraZeneca has reported that its combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) has decreased the rate of moderate or severe exacerbations caused by chronic obstructive pulmonary disease (COPD).
PureTech to assess LYT-100 for Covid-19 respiratory complications
PureTech Health has plans to conduct a clinical trial to assess its LYT-100 (deupirfenidone) drug candidate to treat serious respiratory complications that persist even after resolution of Covid-19 infection.
Athersys and UH Cleveland trial stem cell therapy for Covid-19
Athersys and University Hospitals Cleveland Medical Center (UH Cleveland) have initiated the first clinical site for the MACOVIA trial of MultiStem Cell Therapy to treat Covid-19.
Coronavirus treatment: Vaccines/drugs in the pipeline for COVID-19
Here are the potential human coronavirus vaccines/drugs pharmaceutical companies across the world are developing following the Wuhan coronavirus outbreak (COVID-19).
Bausch Health initiates VIRAZOLE trial in Covid-19 patients
Bausch Health Companies has initiated a clinical trial programme in Canada to evaluate the investigational use of VIRAZOLE (Ribavirin for Inhalation Solution, USP).
United Therapeutics’ Tyvaso meets goals in PH-ILD patients
United Therapeutics has reported that the Tyvaso (treprostinil) inhalation solution met all primary and secondary endpoints in the Phase III INCREASE trial involving patients with pulmonary hypertension caused by interstitial lung disease (PH-ILD).
Novartis discontinues asthma drug candidate fevipiprant following another Phase III trial failure
Shares in Gossamer Bio, which has a lead drug candidate with a similar mechanism of action to fevipiprant, fell following Novartis’ recent announcement.